Digital weight management and clinical weight-loss platforms
Strategic Profile
The company reported 2.7 million total subscribers and 197,000 clinical subscribers as of Q1 2026, with clinical subscription revenue up 32% year-over-year to $39 million. WW added FDA-approved Ozempic pill (semaglutide) to its Med+ formulary effective May 1, 2026, and announced plans to offer Eli Lilly's Foundayo (orforglipron) effective April 9, 2026, reflecting a strategic pivot toward higher-margin clinical and premium subscription tiers.
Cyborg Score Rationale
Q1 2026 revenue was $168 million with a net loss of $52 million and adjusted EBITDA loss of $1.8 million. While clinical revenue growth is strong (32% YoY) and ARPU rose 13%, the company carries $465 million in high-rate term debt with negative operating cash flow. Full-year 2026 guidance projects $620–$635 million revenue and $105–$115 million adjusted EBITDA.
Top Insights
Q1 2026 saw strong clinical revenue growth (+32% YoY) and Core+ subscriber growth (+6% YoY), while overall revenue declined 10% but ARPU rose 13% with gross margin near record highs.
WW added Eli Lilly's Foundayo GLP-1 medication effective April 9, 2026, with self-pay pricing starting at $149/month, expanding its clinical offerings beyond traditional behavioral weight management.
The board appointed Lisa Gavales and Sue Gove as independent directors on April 7, 2026, expanding the board to six fully independent members with consumer, digital, and senior leadership expertise to support strategic transformation.
The stock traded in a 52-week range of $8.37 to $46.95, hitting its 52-week low of $8.37 on May 8, 2026.
Named Competitors
Noom — Behavioral-focused digital weight management platform
Calibrate — Telehealth GLP-1 medication and weight loss coaching
MyFitnessPal — Digital nutrition tracking and fitness platform
Ro — Telehealth platform including GLP-1 weight loss prescriptions
Recent Developments
(June 2026) WW filed a proxy statement on June 4, 2026, outlining shareholder voting and corporate governance matters.
(May 2026) Q1 2026 earnings reported on May 7, 2026, showing 2.7 million total subscribers, 197,000 clinical subscribers (+46% YoY), and $168 million revenue with $39 million clinical subscription revenue (+32% YoY).
(May 2026) WW announced plans to use up to $40 million of cash to prepay term loan principal in May 2026, including $25–$30 million for the annual cash sweep due June 24 and up to $10 million via voluntary solicitation.
(April 2026) WW announced it would offer Eli Lilly's newly FDA-approved oral GLP-1 Foundayo through its Med+ program beginning April 9, 2026.
Open the full interactive WW International, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.